<DOC>
	<DOCNO>NCT02331173</DOCNO>
	<brief_summary>The purpose study evaluate subject X-linked retinoschisis clinical setting collect data disease progression .</brief_summary>
	<brief_title>Clinical Evaluation Patients With X-linked Retinoschisis</brief_title>
	<detailed_description>The objective study evaluate subject XLRS clinical set gather data disease progression . The data study enhance understanding natural history rare disease facilitate appropriately power safety study future gene therapy trial human .</detailed_description>
	<mesh_term>Retinoschisis</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<criteria>Main Study : Clinical diagnosis consistent XLRS Documented disease cause RS1 mutation 7 year age older Able provide inform consent/assent Male CAI substudy : • Presence maculoschisis Main Study : • Other eye disease might affect result ( e.g . history retinal detachment , glaucoma , cataracts prohibit imaging , eye pathology opinion investigator would preclude enrollment ) CAI Substudy : Exclusion Criteria Already treat CAIs Previous document failure respond CAI treatment Any drugspecific contraindication/precaution list ( www.micromedex.com ) : Topical Eye Drop Dorzolamide Hydrochloride Contraindications : • hypersensitivity dorzolamide product , include sulfa allergy Precautions : dorzolamide sulfonamide absorb systemically , sulfonamide hypersensitivity reaction may occur angleclosure glaucoma concomitant use oral carbonicanhydrase inhibitor conjunctivitis lid reaction report chronic administration moderate severe renal ( CrCl le 30 mL/min ) hepatic insufficiency ocular infection inflammation recent ocular surgery Topical Eye Drop Brinzolamide Contraindications : • hypersensitivity component product , include sulfa allergy Precautions : concomitant use oral carbonic anhydrase inhibitor recommend contact lens use ; remove contact lenses prior administration , allow 15 minute reinsertion hypersensitivity sulfonamide ; severe reaction may occur ; discontinue sign symptom appear low corneal endothelial cell count ; increase risk corneal edema renal impairment , severe ( CrCl le 30 mL/min ) ; use recommend</criteria>
	<gender>Male</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>XLRS</keyword>
	<keyword>RS1</keyword>
	<keyword>maculoschisis</keyword>
</DOC>